Rocket Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Rocket Pharmaceuticals's earnings have been declining at an average annual rate of -22.4%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-22.4%
Earnings growth rate
-10.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -78.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain
Dec 02Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09Revenue & Expenses Breakdown
How Rocket Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -258 | 98 | 176 |
| 30 Jun 24 | 0 | -253 | 90 | 180 |
| 31 Mar 24 | 0 | -249 | 80 | 185 |
| 31 Dec 23 | 0 | -246 | 73 | 186 |
| 30 Sep 23 | 0 | -253 | 68 | 194 |
| 30 Jun 23 | 0 | -249 | 64 | 191 |
| 31 Mar 23 | 0 | -237 | 60 | 181 |
| 31 Dec 22 | 0 | -222 | 56 | 165 |
| 30 Sep 22 | 0 | -199 | 51 | 148 |
| 30 Jun 22 | 0 | -192 | 46 | 144 |
| 31 Mar 22 | 0 | -172 | 43 | 127 |
| 31 Dec 21 | 0 | -169 | 42 | 124 |
| 30 Sep 21 | 0 | -186 | 40 | 142 |
| 30 Jun 21 | 0 | -165 | 35 | 124 |
| 31 Mar 21 | 0 | -155 | 33 | 116 |
| 31 Dec 20 | 0 | -140 | 29 | 105 |
| 30 Sep 20 | 0 | -99 | 25 | 70 |
| 30 Jun 20 | 0 | -89 | 23 | 63 |
| 31 Mar 20 | 0 | -82 | 21 | 60 |
| 31 Dec 19 | 0 | -77 | 18 | 58 |
| 30 Sep 19 | 0 | -85 | 15 | 67 |
| 30 Jun 19 | 0 | -82 | 13 | 66 |
| 31 Mar 19 | 0 | -79 | 8 | 62 |
| 31 Dec 18 | 0 | -75 | 13 | 53 |
| 30 Sep 18 | 0 | -54 | 11 | 34 |
| 30 Jun 18 | 0 | -44 | 11 | 26 |
| 31 Mar 18 | 0 | -32 | 13 | 18 |
| 31 Dec 17 | 0 | -20 | 5 | 15 |
| 30 Sep 17 | 0 | -16 | 4 | 12 |
| 30 Jun 17 | 0 | -11 | 2 | 9 |
| 31 Mar 17 | 0 | -9 | 2 | 7 |
| 31 Dec 16 | 0 | -8 | 2 | 6 |
Quality Earnings: RCKT is currently unprofitable.
Growing Profit Margin: RCKT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RCKT is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare RCKT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: RCKT has a negative Return on Equity (-78.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 11:30 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rocket Pharmaceuticals, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Gregory Harrison | BofA Global Research |
| Yun Zhong | BTIG |